Molecular therapeutics in breast cancer
1 – 10 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer
(
- Contribution to journal › Article
- 2022
-
Mark
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
(
- Contribution to journal › Article
- 2021
-
Mark
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
(
- Contribution to journal › Article
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
(
- Contribution to journal › Article
-
Mark
An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
(
- Contribution to journal › Article
-
Mark
Molecular analyses of triple-negative breast cancer in the young and elderly
(
- Contribution to journal › Article
-
Mark
Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study
(
- Contribution to journal › Article
-
Mark
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Whole-genome sequencing of triple negative breast cancers in a standard population-based clinical setting
2020) UK Interdisciplinary Breast Cancer Symposium 2020 In Breast Cancer Research and Treatment 180. p.531-532(
- Contribution to journal › Published meeting abstract
-
Mark
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
(
- Contribution to journal › Article